Literature DB >> 8376608

Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes.

M A Morsy1, E L Alford, A Bett, F L Graham, C T Caskey.   

Abstract

100% of primary human hepatocytes infected with an adenoviral vector carrying beta-galactosidase expressed the exogenous gene. Expression was also achieved in > 40% of adult mouse hepatocytes in vivo. Normal levels of activity were achieved in mouse ornithine transcarbamylase (OTC)-deficient primary hepatocytes using another adenoviral vector carrying human OTC cDNA. Study of OTC-deficient primary human hepatocytes from a single patient confirmed the utility of adenoviral delivery of OTC. We describe adenoviral-mediated exogenous gene expression in human and mouse hepatocytes in vitro and in mouse liver in vivo. Data suggest that adenoviral vectors may be useful for correcting OTC deficiency.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376608      PMCID: PMC288307          DOI: 10.1172/JCI116739

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Participation of two human cytomegalovirus immediate early gene regions in transcriptional activation of adenovirus promoters.

Authors:  M J Tevethia; D J Spector; K M Leisure; M F Stinski
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

2.  Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines.

Authors:  G Chaloner-Larsson; G Contreras; J Furesz; D W Boucher; D Krepps; G R Humphreys; S M Mohanna
Journal:  Can J Public Health       Date:  1986 Sep-Oct

3.  Histochemical staining of clonal mammalian cell lines expressing E. coli beta galactosidase indicates heterogeneous expression of the bacterial gene.

Authors:  G R MacGregor; A E Mogg; J F Burke; C T Caskey
Journal:  Somat Cell Mol Genet       Date:  1987-05

4.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

5.  Cis-acting induction of adenovirus transcription.

Authors:  R B Gaynor; A J Berk
Journal:  Cell       Date:  1983-07       Impact factor: 41.582

6.  Ornithine transcarbamylase deficiency in mutant mice I. Studies on the characterization of enzyme defect and suitability as animal model of human disease.

Authors:  I A Qureshi; J Letarte; R Ouellet
Journal:  Pediatr Res       Date:  1979-07       Impact factor: 3.756

7.  Hepatocyte proliferation in vitro: its dependence on the use of serum-free hormonally defined medium and substrata of extracellular matrix.

Authors:  R Enat; D M Jefferson; N Ruiz-Opazo; Z Gatmaitan; L A Leinwand; L M Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans.

Authors:  K M Wong; A J Levine
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

9.  Activation and inhibition of expression of the 72,000-Da early protein of adenovirus type 5 in mouse cells constitutively expressing an immediate early protein of herpes simplex virus type 1.

Authors:  M L Tremblay; S P Yee; R H Persson; S Bacchetti; J R Smiley; P E Branton
Journal:  Virology       Date:  1985-07-15       Impact factor: 3.616

10.  Tn5 mutagenesis of the transforming genes of human adenovirus type 5.

Authors:  R D McKinnon; S Bacchetti; F L Graham
Journal:  Gene       Date:  1982 Jul-Aug       Impact factor: 3.688

View more
  12 in total

1.  A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector.

Authors:  Shuji Kubo; Kohnosuke Mitani
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  In vivo nitrogen metabolism in ornithine transcarbamylase deficiency.

Authors:  M Yudkoff; Y Daikhin; I Nissim; A Jawad; J Wilson; M Batshaw
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

Authors:  H Zhou; W O'Neal; N Morral; A L Beaudet
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  Interrogation of the Atherosclerosis-Associated SORT1 (Sortilin 1) Locus With Primary Human Hepatocytes, Induced Pluripotent Stem Cell-Hepatocytes, and Locus-Humanized Mice.

Authors:  Xiao Wang; Avanthi Raghavan; Derek T Peters; Evanthia E Pashos; Daniel J Rader; Kiran Musunuru
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-02       Impact factor: 8.311

5.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.

Authors:  G P Gao; Y Yang; J M Wilson
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses.

Authors:  J M Bergelson; A Krithivas; L Celi; G Droguett; M S Horwitz; T Wickham; R L Crowell; R W Finberg
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

Authors:  A J Bett; W Haddara; L Prevec; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

8.  Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency.

Authors:  S E Raper; J M Wilson; M Yudkoff; M B Robinson; X Ye; M L Batshaw
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

9.  In vivo measurement of ureagenesis with stable isotopes.

Authors:  M Yudkoff; Y Daikhin; X Ye; J M Wilson; M L Batshaw
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

10.  Patient selection may affect gene therapy success. Dominant negative effects observed for ornithine transcarbamylase in mouse and human hepatocytes.

Authors:  M A Morsy; J Z Zhao; T T Ngo; A W Warman; W E O'Brien; F L Graham; C T Caskey
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.